1. Home
  2. LCFY vs LYRA Comparison

LCFY vs LYRA Comparison

Compare LCFY & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCFY
  • LYRA
  • Stock Information
  • Founded
  • LCFY 2009
  • LYRA 2005
  • Country
  • LCFY Australia
  • LYRA United States
  • Employees
  • LCFY N/A
  • LYRA N/A
  • Industry
  • LCFY
  • LYRA Medical/Dental Instruments
  • Sector
  • LCFY
  • LYRA Health Care
  • Exchange
  • LCFY Nasdaq
  • LYRA Nasdaq
  • Market Cap
  • LCFY 5.8M
  • LYRA 5.8M
  • IPO Year
  • LCFY 2022
  • LYRA 2020
  • Fundamental
  • Price
  • LCFY $3.98
  • LYRA $24.28
  • Analyst Decision
  • LCFY
  • LYRA Buy
  • Analyst Count
  • LCFY 0
  • LYRA 2
  • Target Price
  • LCFY N/A
  • LYRA $100.00
  • AVG Volume (30 Days)
  • LCFY 12.9K
  • LYRA 1.9M
  • Earning Date
  • LCFY 06-17-2025
  • LYRA 05-06-2025
  • Dividend Yield
  • LCFY N/A
  • LYRA N/A
  • EPS Growth
  • LCFY N/A
  • LYRA N/A
  • EPS
  • LCFY N/A
  • LYRA N/A
  • Revenue
  • LCFY $2,668,385.00
  • LYRA $1,185,000.00
  • Revenue This Year
  • LCFY N/A
  • LYRA N/A
  • Revenue Next Year
  • LCFY N/A
  • LYRA $1,286.17
  • P/E Ratio
  • LCFY N/A
  • LYRA N/A
  • Revenue Growth
  • LCFY N/A
  • LYRA N/A
  • 52 Week Low
  • LCFY $2.20
  • LYRA $3.81
  • 52 Week High
  • LCFY $11.23
  • LYRA $37.50
  • Technical
  • Relative Strength Index (RSI)
  • LCFY 43.83
  • LYRA 76.38
  • Support Level
  • LCFY $3.86
  • LYRA $22.22
  • Resistance Level
  • LCFY $4.30
  • LYRA $27.42
  • Average True Range (ATR)
  • LCFY 0.21
  • LYRA 4.12
  • MACD
  • LCFY -0.02
  • LYRA 2.36
  • Stochastic Oscillator
  • LCFY 19.78
  • LYRA 60.76

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: